Proof-of-Principle INNOGAP
Following the deadline of October 15, 2019, Unitec received 14 submitted projects for INNOGAP funding. After evaluation, the projects will be reviewed by the Conseil Unitec on December 18.
|
|
|
Deadline for BRIDGE Proof of Concept : December 9
BRIDGE Proof of Concept helps apply research results and gain the confidence needed to make a market entry. The projects may target innovations of all kinds from all research areas.
|
|
|
Dr Léo Duchêne recognised for his invention on solid batteries developed at UNIGE & EMPA.
On October 16, Leo Duchêne received a prestigious Research Award from the Electrochemical Society in Atlanta USA.
The invention, selected by Unitec as most promising for 2019,was developed by EMPA together with UNIGE co-inventors Prof. H. H. Hagemann and Dr. R.-Y. Moury.
|
|
|
Last May, Unitec organised its bi-annual serie of courses on Research Results Commercialization and Technology Transfer.
For those who missed it, you can find the presentations here.
|
|
HUG Innovation Day
On October 31st, from 1 pm to 6 pm, the HUG Innovation Day will present pitches contests, awards and many others innovations.
As part of the jury, Unitec provides its expertise in the selection and evaluation of the submitted projects.
Information, program, registration here.
|
|
|
|
Innovation from the lab to your life
For Science Innovation Hub's inauguration on November 9 at 6 pm, Prof. O. Shoseyov, (Hebrew University of Jerusalem), will talk about Nature’s Gift; Materials for the future.
With contributions from G. Ribordy, (Id Quantique) as well as Profs. E. Allémann and J.-P. Wolf. (UNIGE)
Entrance free but registration necessary. More information here.
|
|
|
|
Vente exceptionnelle d'une spin-off UNIGE d'un anticorps monoclonal approuvé par la FDA pour mise sur le marché américain
Spin-off de l’Université de Genève, la biotech Novimmune a cédé son produit phare, l’emapalumab, au groupe pharmaceutique suédois Sobi. L’emapalumab est un candidat-médicament développé pour lutter contre la lymphohistiocytose hémophagocytaire primaire, une maladie orpheline touchant surtout les bébés et les enfants en bas âge, au taux de mortalité de 40% et contre laquelle aucun traitement n’existe pour l’instant. La transaction porte sur un montant de 515 millions de francs, dont 400 millions déjà engagés dans le cadre d’un accord de licence exclusif.
|
|
|
Spin-Off AMAL Therapeutics gets acquired by Boehringer Ingelheim
The spin-off from the University of Geneva and of Hôpitaux universitaires de Genève, who is developing new cancer vaccines, has been acquired by Boehringer Ingelheim.
The total amount of the transaction may reach 325 millions euros (about 362 millions Swiss francs), split between an initial payment and clinical milestones. An additional amount of up to 100 millions euros (about 111 millions Swiss francs) is linked to commercial objectives. More info here.
|
|
|
Unitec is proud to announce the creation of 4 spin-offs:
|
|
|
Adiposs is a Swiss biotech start-up company developing medical imaging products and technologies for early detection of cachexia
|
|
|
|
FoRx Therapeutics will develop anti-cancer drugs directed against molecular targets linked to DNA replication stress
|
|
|
|
MPC Therapeutics is developping mitochondrial pyruvate carrier inhibitors to treat metabolic and neurodegenerative diseases
|
|
|
|
Orion Biotechnology Switzerland is developing chemokine analogue-based therapeutics in the field of oncology, neuro-inflammation and HIV prevention.
|
|
|
|
|
|
